United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares
Martine A. Rothblatt, CEO of United Therapeutics Corp., sold 9,500 shares of company stock for approximately $5.38 million. This sale followed the exercise of stock options and was conducted under a pre-arranged 10b5-1 trading plan. The transactions occurred while UTHR stock is near its 52-week high, with the company's valuation currently appearing overvalued according to InvestingPro analysis.
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares
Martine A. Rothblatt, CEO of United Therapeutics Corp., sold 9,500 shares for $5.38 million on May 20, 2026, after exercising options for the same number of shares. These transactions were executed under a pre-arranged 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, with the company also recently reporting mixed financial results and positive clinical trial news.
United Therapeutics CEO Rothblatt sells $5.4m in common stock
Martine A. Rothblatt, CEO of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $5.4 million worth of common stock on May 19, 2026, after exercising stock options. These transactions were conducted under a pre-arranged 10b5-1 trading plan. The sale occurred while UTHR shares were trading near their 52-week high, and the stock is considered overvalued according to InvestingPro analysis despite aggressive share buybacks by management.
United Therapeutics CEO Rothblatt sells $5.4m in common stock
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.4 million worth of common stock on May 19, 2026, following the exercise of stock options. These transactions were part of a pre-arranged 10b5-1 trading plan. The company's stock has seen an 83% increase over the past year, trading near its 52-week high, despite recent Q1 earnings missing analyst expectations.
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock
Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp, sold 9,500 shares for $5.4 million on May 15, 2026, executed via a pre-arranged 10b5-1 trading plan. On the same day, she also acquired 9,500 shares through stock option exercises for $1.38 million. These transactions occurred as the stock traded near its 52-week high, with InvestingPro analysis suggesting it is currently overvalued.
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock
Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp, sold $5.4 million in company stock after exercising stock options as part of a pre-arranged trading plan. Despite this, she retains significant direct and indirect holdings. The sale occurred near the stock's 52-week high, though InvestingPro analysis suggests it might be overvalued.
Inhaled Tyvaso preserves lung function, cuts IPF risks in trial
United Therapeutics announced that its TETON-1 and TETON-2 studies evaluating nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF) showed statistically significant improvements in preserving lung function and reducing clinical worsening events. The full results have been published in The New England Journal of Medicine and presented at the ATS International Conference. Based on these findings, United Therapeutics plans to seek priority review for a supplemental New Drug Application with the FDA to add IPF as a labeled indication for nebulized Tyvaso.
Experimental PAH pill ralinepag cuts worsening risk 55% in Phase 3
United Therapeutics announced that its experimental drug, ralinepag, a once-daily oral prostacyclin receptor agonist, met its primary endpoint in the Phase 3 ADVANCE OUTCOMES study, significantly reducing the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH) by 55%. The drug also showed statistical significance in improving secondary endpoints, including reducing N-terminal pro-B-type natriuretic peptide levels and enhancing exercise capacity. United Therapeutics plans to submit a New Drug Application for ralinepag to the FDA by the second half of 2026, aiming to redefine PAH treatment.
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics Corporation has received FDA clearance to begin a clinical trial (EXPRESS study) for its UHeart xenotransplantation, which involves a 10-gene edited pig heart. The study will initially enroll up to two participants with end-stage heart failure, evaluating safety and efficacy with the potential for expansion to support a Biologics License Application. This marks a significant step in addressing the critical shortage of human organs for transplant patients.
Leuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHR
Leuthold Group LLC increased its stake in United Therapeutics Corporation by 41.4% in the fourth quarter, purchasing 3,126 additional shares to bring its total to 10,672 shares valued at approximately $5.2 million. This comes despite significant insider selling from executives like CEO Martine Rothblatt and CFO James Edgemond. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating and an average price target of $619.42, even after a recent earnings miss.
United Therapeutics stock (US9113631090): FDA clears first UHeart xenotransplantation trial
The FDA has cleared United Therapeutics to begin its first-in-human clinical study for UHeart, a gene-edited pig-derived heart designed for xenotransplantation. This move expands the company's pipeline beyond its core pulmonary hypertension drugs and positions it at the forefront of advanced biotechnology and medical devices. While the xenotransplantation program offers speculative long-term revenue potential, it adds a high-risk, high-reward development track to the company's established, cash-generating pulmonary hypertension franchise.
United Therapeutics stock (US9113631090): fresh data push at ATS 2026 keeps pipeline in focus
United Therapeutics is preparing to present 12 new data presentations at the American Thoracic Society (ATS) International Conference 2026, focusing on its pulmonary hypertension franchise and broader cardiopulmonary pipeline. This comes as the company also recently resubmitted its New Drug Application (NDA) for Tyvaso DPI to the FDA. The article highlights these events as key catalysts for investors, emphasizing the company's established position in specialized therapeutics and its efforts in advanced technologies like organ manufacturing research.
UTHR - United Therapeutics Corp Stock Price and Quote
This article provides comprehensive stock information for United Therapeutics Corp (UTHR), including its current stock price, key financial metrics, recent news, analyst ratings, and insider transactions. It highlights the company's recent positive phase 3 trial results for ralinepag and TETON-1, and details a series of stock options exercises and sales by company executives.
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics (NASDAQ: UTHR) announced that the FDA has cleared its Investigational New Drug application for a clinical study of its UHeart, a pig-derived heart with 10 gene edits, for xenotransplantation. The EXPRESS study will initially enroll up to two participants, with plans to expand and support a Biologics License Application based on safety and efficacy data. This marks a significant advancement in xenotransplantation, aiming to address the critical shortage of organs for patients with end-stage heart disease.
Varda Space and United Therapeutics to test drugs in space microgravity
Varda Space Industries and United Therapeutics Corp. have partnered to explore the use of microgravity for drug development, aiming to validate space technologies for the pharmaceutical industry. Varda will send drug samples to orbit in uncrewed capsules for chemical processing, with scientists studying the effects of microgravity on the molecules upon their return to Earth. This collaboration represents a significant step towards commercial-scale drug manufacturing in space, leveraging Varda's recent success in crystallizing the HIV drug ritonavir.
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock
Martine Rothblatt, CEO of United Therapeutics Corp., sold 9,500 shares of company stock for approximately $5.5 million on May 13, 2026, following the exercise of stock options. This sale was conducted under a pre-arranged 10b5-1 trading plan. Despite the CEO's sales, management has been actively buying back shares, indicating confidence in the company, which recently reported Q1 2026 earnings below analyst expectations and announced a partnership with Varda Space Industries.
United Therapeutics director Mesa Nilda sells $150,139 in stock
Mesa Nilda, a director at United Therapeutics Corp (NASDAQ:UTHR), sold 258 shares of company stock worth $150,139 on May 12, 2026, with the stock trading near its 52-week high. The sale follows United Therapeutics reporting first-quarter earnings that missed analyst expectations and a Neutral rating from BTIG, though the company is also pursuing innovation through a collaboration with Varda Space Industries.
Varda’s First Pharma Deal Brings Space Drugs Closer to Reality
Varda Space Industries has secured its first pharmaceutical deal with United Therapeutics Corporation to develop new drug formulations in microgravity for rare pulmonary diseases. This collaboration aims to leverage the unique environment of space to create purer and more uniform drug crystals, pushing commercial in-orbit manufacturing closer to reality. Varda, a pioneer in this field, hopes to transition from microgravity science to tangible patient benefits on Earth.
Varda Space, United Therapeutics to test lung drugs in orbit
Varda Space and United Therapeutics are collaborating to test lung drugs in orbit. This partnership aims to leverage the microgravity environment of space to advance the development of new treatments for lung conditions.
United Therapeutics director Mesa Nilda sells $150,139 in stock
Mesa Nilda, a director at United Therapeutics Corp (NASDAQ: UTHR), sold 258 shares of the company's common stock for a total of $150,139 on May 12, 2026. This transaction occurred while the stock is trading near its 52-week high, and an InvestingPro analysis suggests UTHR is currently overvalued. The sale follows a recent first-quarter earnings report where United Therapeutics missed analyst expectations for revenue, net income, and EPS.
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease
Varda Space Industries and United Therapeutics Corporation are collaborating to research the use of microgravity to develop enhanced formulations for rare pulmonary disease treatments. This partnership will involve processing small molecule medicines on Varda's orbital manufacturing platform, leveraging microgravity's effect on crystal structures to improve drug stability, bioavailability, and delivery. The goal is to translate space-based manufacturing into tangible benefits for patients suffering from life-threatening pulmonary conditions on Earth.
United Therapeutics CFO James Edgemond sells $5.7m in stock
United Therapeutics CFO James Edgemond sold approximately $5.7 million worth of company stock on May 11, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan established in October 2025, with the sales occurring as the stock approaches its 52-week high. The sale follows recent financial results where United Therapeutics missed analyst expectations for revenue and EPS.
United Therapeutics CFO James Edgemond sells $5.7m in stock
James Edgemond, CFO and Treasurer of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $5.7 million worth of company stock on May 11, 2026, after exercising stock options. These transactions were conducted under a Rule 10b5-1 trading plan established in October 2025. The sales occurred while United Therapeutics stock was trading near its 52-week high, with InvestingPro analysis suggesting the stock is currently overvalued.
United Therapeutics (UTHR) up 5.7% since last earnings report: Can it continue?
United Therapeutics (UTHR) has seen a 5.7% increase in its stock price since its last earnings report. Investors are now looking to see if the company can maintain this positive momentum in the upcoming quarter. The article will likely delve into factors influencing UTHR's performance and future outlook.
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
United Therapeutics Corporation announced that its drug Ralinepag significantly reduced the risk of clinical worsening in a pivotal pulmonary arterial hypertension study by 55%, demonstrating exceptional and highly statistically significant efficacy. This press release highlights the positive clinical trial results for Ralinepag. The company's stock, UTHR, is also tracked by Quantisnow, a market data and news platform for investors.
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation announced that its Chief Financial Officer and Treasurer, James Edgemond, will present a company overview and update at the RBC Capital Markets Global Healthcare Conference on May 19, 2026. The presentation will be accessible via a live webcast on the company's website, with an archived version available for 90 days afterward. The company, founded by Martine Rothblatt, focuses on developing therapies for rare diseases like pulmonary arterial hypertension and pioneering transplantable organs.
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced that James Edgemond, Chief Financial Officer and Treasurer, will present a company overview and update at the RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for Tuesday, May 19, 2026, from 9:30 to 9:55 a.m. EST, and will be accessible via a live webcast on the United Therapeutics website. An archived recording will be available for 90 days following the event.
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
United Therapeutics Corporation announced it will present 12 new data presentations at the American Thoracic Society (ATS) International Conference from May 15-20 in Orlando. The presentations will include new data from the TETON-1 and ADVANCE OUTCOMES pivotal studies for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), respectively. Additionally, interim analyses from studies like TETON-PPF, PHINDER, and ARTISAN, focusing on progressive pulmonary fibrosis and interstitial lung disease, will be shared, providing insights into managing these diseases.
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced that its Chief Financial Officer and Treasurer, James Edgemond, will present a company overview and update at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 19, 2026. This presentation will be accessible via a live webcast on the company's website, with an archived version available for 90 days afterward. The company, founded by Martine Rothblatt, focuses on transforming rare disease treatments and pioneering alternatives for transplantable organs.
Hedge Fund and Insider Trading News: Ken Griffin, Scott Bessent, Warren Buffett, CastleKnight Management, Saba Capital, Brevan Howard, TCI Fund Management, Aminex PLC (AEX), United Therapeutics Corp (UTHR), and More
This article provides a roundup of recent hedge fund and insider trading news involving prominent figures like Ken Griffin, Scott Bessent, and Warren Buffett, alongside updates on firms such as CastleKnight Management, Saba Capital, and TCI Fund Management. It also highlights specific insider transactions, including those for Aminex PLC (AEX) and United Therapeutics Corp (UTHR). The report touches on macroeconomic warnings, fund performance, and strategic shifts within the hedge fund industry, while also promoting an AI stock pick.
United Therapeutics(UTHR.US) Officer Sells US$5.5 Million in Common Stock
An officer at United Therapeutics (UTHR.US) recently sold common stock valued at $5.5 million. This transaction indicates insider activity within the company. Investors often monitor such sales for insights into management's perception of the company's future prospects.
United Therapeutics chairperson & CEO Rothblatt sells $5.5m in stock
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $5.5 million worth of company stock following the exercise of stock options. This sale, conducted via a pre-arranged 10b5-1 trading plan, happened while UTHR shares traded near their 52-week high, though InvestingPro analysis suggests the stock is currently overvalued. The transactions have adjusted Rothblatt’s direct and indirect holdings in the company.
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
United Therapeutics Corporation announced it will present 12 new data presentations at the American Thoracic Society (ATS) International Conference regarding its commercial and development portfolio. Key presentations include results from the TETON-1 study in idiopathic pulmonary fibrosis (IPF) and the ADVANCE OUTCOMES study in pulmonary arterial hypertension (PAH), along with interim analyses from studies like TETON-PPF, PHINDER, and ARTISAN. These findings are expected to provide significant clinical insights for managing these life-threatening diseases.
Assessing United Therapeutics (UTHR) Valuation After A Strong Year Of Shareholder Returns
United Therapeutics (UTHR) has seen significant shareholder returns, with an 84.8% 1-year total return. Despite a recent short-term decline, its stock price of $569.18 is considered undervalued by a narrative fair value of $644.08, highlighting the potential of its pulmonary, organ platform, and innovation pipeline. However, a deeper discounted cash flow analysis suggests a much higher intrinsic value of $1,822.34 per share, posing a question for investors on the true valuation.
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2026 Earnings Call Transcript
United Therapeutics (NASDAQ: UTHR) reported Q1 2026 earnings, missing expectations with an EPS of $5.82 against an anticipated $7.00. Despite this, the company projects significant growth, expecting revenue to reach $4 billion by the end of 2027, driven by two new therapeutics, Tyvaso for IPF and ralinepag for PAH, which have shown superior clinical outcomes in Phase III trials. The company also announced the development of RALDPI, an inhaled formulation of ralinepag, aiming to become their biggest product for IPF, PAH, ILD, and PPF, with regulatory strategies underway for multiple formulations.
United Therapeutics EVP Paul Mahon sells $4.87m in common stock
Paul A. Mahon, EVP and General Counsel of United Therapeutics Corp (NASDAQ:UTHR), exercised stock options then sold 8,300 shares, totaling approximately $4.87 million, on May 7, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold at prices ranging from $582.42 to $597.54, occurring while the stock is near its 52-week high, despite recent Q1 earnings missing analyst expectations. Following these transactions, Mr. Mahon directly holds 45,172 shares of the company's common stock.
Will Softer Q1 2026 Results Test How United Therapeutics (UTHR) Funds Its Innovation Ambitions?
United Therapeutics (UTHR) reported softer Q1 2026 results with lower-than-expected sales and net income, raising questions about its ability to fund future innovation. Despite a promising pipeline in pulmonary disease and organ technologies, including positive ralinepag Phase 3 data, investors are now scrutinizing how reliably current products can support these ambitions. The company's investment narrative is centered on its pipeline offsetting pressure on established PAH drugs, with the recent TETON IPF studies for Tyvaso being a significant growth driver, though increasing competition poses a risk.
United Therapeutics EVP Paul Mahon sells $4.87m in common stock
United Therapeutics EVP Paul A. Mahon sold $4.87 million worth of common stock on May 7, 2026, after exercising 8,300 stock options. The transactions were conducted under a pre-arranged 10b5-1 trading plan and occurred while the company's stock was near its 52-week high. Despite recent first-quarter earnings missing analyst expectations, the stock has shown resilience, and Mahon still directly holds 45,172 shares.
United Therapeutics: Q1 Earnings Snapshot
United Therapeutics Corp. reported first-quarter earnings of $274.9 million, or $5.82 per share, missing Wall Street expectations of $6.73 per share. The drugmaker also posted revenue of $781.5 million, which fell short of analysts' average estimate of $800.4 million. This financial performance indicates a challenging quarter for the company compared to analyst predictions.
UNITED THERAPEUTICS Corp 1Q 2026: Revenue $781.5M, EPS $5.82— 10-Q Summary
UNITED THERAPEUTICS Corp reported its first-quarter 2026 results, showing a slight decrease in revenue to $781.5 million and diluted EPS of $5.82 compared to the previous year. Net income also fell to $274.9 million. Despite these declines, the company saw growth in Tyvaso DPI sales and made significant operational and commercial advancements, including positive phase 3 results for pipeline drugs and the first UKidney transplant.
United Therapeutics CEO Rothblatt sells $5.47m in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for $5.47 million and simultaneously acquired the same number of shares by exercising stock options under a pre-arranged 10b5-1 trading plan. These transactions took place while the stock is near its 52-week high, despite the company recently reporting first-quarter results that missed analyst expectations for revenue and net income.
United Therapeutics pairs a $2B buyback with a 2% revenue dip
United Therapeutics (UTHR) reported a 2% decrease in total revenues for Q1 2026, reaching $781.5 million, down from $794.4 million in Q1 2025. Despite the revenue dip, the company announced a new $2.0 billion share repurchase program and promising clinical trial results for ADVANCE OUTCOMES and TETON-1 studies, which could expand future growth. Net income for the quarter also decreased by 15% to $274.9 million.
Transcript: United Therapeutics Q1 2026 Earnings Conference Call
United Therapeutics reported strong Q1 2026 revenues of $782 million, with Tyvaso contributing substantially. The company highlighted promising clinical trial results for Ralinepag in PAH and Tyvaso in IPF, expecting these to significantly increase future revenue and potentially double current figures. Strategic plans include expanding market presence through new formulations and regulatory approvals, emphasizing a "multiple shots on goal" approach and relentless innovation.
Earnings call transcript: United Therapeutics misses Q1 2026 earnings forecast
United Therapeutics (UTHR) reported a miss on its Q1 2026 earnings forecast, with an EPS of $5.82 against an expected $6.99 and revenue of $782 million against a forecast of $798.85 million. Despite the miss, the stock rose by 2.23% in pre-market trading due to investor optimism about future growth prospects driven by new product launches and market expansion, particularly with ralinepag and TYVASO. The company remains confident in achieving sustained double-digit growth and expects these products to significantly boost revenue in the coming years.
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
United Therapeutics Corporation announced its first-quarter 2026 financial results, reporting a 2% year-over-year decrease in total revenues to $781.5 million. Despite this, the company highlighted positive clinical trial results for ADVANCE OUTCOMES and TETON-1 studies, aiming to expand future growth and diversify revenue. They also detailed development plans for ralinepag DPI and affirmed commitment to sequential quarterly revenue growth across their portfolio.
United Therapeutics: Q1 Earnings Snapshot
United Therapeutics Corp. (UTHR) reported its first-quarter earnings, which amounted to $274.9 million, or $5.82 per share. These results fell short of Wall Street expectations, with analysts having projected $6.73 per share. The drugmaker also missed revenue forecasts, posting $781.5 million against an expected $800.4 million.
United Therapeutics: Q1 Earnings Snapshot
United Therapeutics Corp. (UTHR) reported Q1 earnings of $274.9 million, or $5.82 per share, missing Wall Street estimates of $6.73 per share. The company's revenue for the quarter was $781.5 million, also falling short of analysts' expectations of $800.4 million. This story was generated by Automated Insights using data from Zacks Investment Research.
United Therapeutics: Q1 Earnings Snapshot
United Therapeutics Corp. reported first-quarter earnings of $274.9 million, or $5.82 per share, which fell short of analyst expectations. The company also missed revenue forecasts, posting $781.5 million against an anticipated $800.4 million. This story was generated by Automated Insights using data from Zacks Investment Research.
Martine Rothblatt, United Therapeutics CEO, sells $5.48m in shares
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.48 million in shares on May 4, 2026. This transaction involved 9,500 shares and was executed under a pre-arranged 10b5-1 trading plan, coinciding with the exercise of stock options. The company has also seen recent positive developments, including an FDA designation for a new product and increased price targets from analysts.
United Therapeutics faces earnings test as IPF expansion looms
United Therapeutics is poised to report first-quarter earnings, with investors focused on the company's core business performance and its upcoming expansion into idiopathic pulmonary fibrosis (IPF) treatment. The company's TETON-1 study for nebulized Tyvaso in IPF met its primary endpoint, leading to significant stock appreciation and positioning the drug as a potential "new IPF standard." Analysts are largely bullish, expecting earnings of $6.99 per share and a consensus price target of $644.62, as the company prepares for regulatory submission and targets a multi-billion dollar market opportunity.
